Literature DB >> 2105921

Bowel complications after radiotherapy for carcinoma of the prostate: the volume effect.

H Mameghan1, R Fisher, J Mameghan, W H Watt, A Tynan.   

Abstract

Late radiation-induced bowel complications were studied in 218 patients treated for localized carcinoma of the prostate by radical radiotherapy at the Prince of Wales Hospital between 1980 and 1986. Mild to moderate toxicity was seen in 38 cases, and severe toxicity requiring surgery occurred in 3 patients. The total actuarial complication rate (by 5 years) for all grades was 24% and for severe complications was 1.8%. Significant patient-related risk factors were older age at the time of radiotherapy (p = 0.035) and a previous history of abdominal operations (p = 0.028). Among treatment-related risk factors only inclusion of the whole pelvis in the irradiated volume had a significant association with this complication (p = 0.015). The risk of bowel complications was not related to the total radiation dose or to the use of interstitial implants as employed in this series.

Entities:  

Mesh:

Year:  1990        PMID: 2105921     DOI: 10.1016/0360-3016(90)90095-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

Review 1.  Periodic health examination, 1991 update: 3. Secondary prevention of prostate cancer. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1991-09-01       Impact factor: 8.262

Review 2.  Low anterior resection syndrome (LARS): cause and effect and reconstructive considerations.

Authors:  Y Ziv; A Zbar; Y Bar-Shavit; I Igov
Journal:  Tech Coloproctol       Date:  2012-10-18       Impact factor: 3.781

3.  Rapid loss of bone mass and strength in mice after abdominal irradiation.

Authors:  Dan Jia; Dana Gaddy; Larry J Suva; Peter M Corry
Journal:  Radiat Res       Date:  2011-08-22       Impact factor: 2.841

4.  Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30.

Authors:  G Borghede; M Sullivan
Journal:  Qual Life Res       Date:  1996-04       Impact factor: 4.147

5.  High-dose-rate brachytherapy combined with long-term hormonal therapy for high-risk prostate cancer: results of a retrospective analysis.

Authors:  Ryoong-Jin Oh; Yasuo Yoshioka; Eiichi Tanaka; Hiroya Shiomi; Iori Sumida; Fumiaki Isohashi; Osamu Suzuki; Koji Konishi; Yoshifumi Kawaguchi; Satoaki Nakamura; Masahiro Kato; Takehiro Inoue
Journal:  Radiat Med       Date:  2006-01

Review 6.  Radiation change in normal organs: an overview of body imaging.

Authors:  H I Libshitz; R A DuBrow; E M Loyer; C Charnsangavej
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

7.  Whole pelvic intensity-modulated radiotherapy for high-risk prostate cancer: a preliminary report.

Authors:  Ji Hyeon Joo; Yeon Joo Kim; Young Seok Kim; Eun Kyung Choi; Jong Hoon Kim; Sang-Wook Lee; Si Yeol Song; Sang Min Yoon; Su Ssan Kim; Jin-Hong Park; Yuri Jeong; Hanjong Ahn; Choung-Soo Kim; Jae-Lyun Lee; Seung Do Ahn
Journal:  Radiat Oncol J       Date:  2013-12-31

8.  Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma.

Authors:  G Sanguineti; S Agostinelli; F Foppiano; P Franzone; S Garelli; M Marcenaro; M Orsatti; V Vitale
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

9.  A prospective comparison of acute intestinal toxicity following whole pelvic versus small field intensity-modulated radiotherapy for prostate cancer.

Authors:  Yeon Joo Kim; Jin-Hong Park; In-Ha Yun; Young Seok Kim
Journal:  Onco Targets Ther       Date:  2016-03-09       Impact factor: 4.147

10.  Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.

Authors:  Gregor Habl; Sonja Katayama; Matthias Uhl; Kerstin A Kessel; Lutz Edler; Juergen Debus; Klaus Herfarth; Florian Sterzing
Journal:  BMC Cancer       Date:  2015-11-07       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.